Concise review: Transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa

Stem Cells

Volumn 29, Issue 6, 2011, Pages 900-906

  Tolar, Jakub ^a   Blazar, Bruce R ^a   Wagner, John E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bone marrow; Cord blood; Epidermolysis bullosa; Extracellular matrix; Regenerative medicine; Stem cell transplantation

Indexed keywords

C7 PROTEIN; MUTANT PROTEIN; PROTEIN; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANALGESIA; BANDAGING TECHNIQUE; BLISTER; CHIMERA; DEBRIDEMENT; EPIDERMOLYSIS BULLOSA; ESOPHAGUS STRICTURE; EXPERIMENTAL MOUSE; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; INFECTION; MOLECULAR MECHANICS; NONHUMAN; NUTRITIONAL SUPPORT; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SCAR FORMATION; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; STEM CELL NICHE; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; CHIMERISM; CLINICAL TRIALS AS TOPIC; COLLAGEN TYPE VII; EPIDERMOLYSIS BULLOSA; EXTRACELLULAR MATRIX PROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; SKIN; STEM CELL NICHE;

ANIMALIA;

EID: 79957595404     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.647     Document Type: Short Survey

References (54)

1. Blanpain C, Fuchs E. Epidermal homeostasis: A balancing act of stem cells in the skin. Nat Rev Mol Cell Biol 2009;10:207-217.
2. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: Mechanisms and clinical consequences. Nat Rev Immunol 2004;4:211-222. (Pubitemid 38339087)
3. Lara-Corrales I, Arbuckle A, Zarinehbaf S et al. Principles of wound care in patients with epidermolysis bullosa. Pediatr Dermatol 2010;27:229-237.
4. Wu Y, Zhao RC, Tredget EE. Concise review: Bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 2010;28:905-915.
5. Murata H, Janin A, Leboeuf C et al. Donor-derived cells and human graft-versus-host disease of the skin. Blood 2007;109:2663-2665. (Pubitemid 46425918)
6. Krause DS, Theise ND, Collector MI et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001;105:369-377. (Pubitemid 32455343)
7. Metaxas Y, Zeiser R, Schmitt-Graeff A et al. Human hematopoietic cell transplantation results in generation of donor-derived epithelial cells. Leukemia 2005;19:1287-1289. (Pubitemid 40946022)
8. Khan FM, Sy S, Louie P et al. Nasal epithelial cells of donor origin after allogeneic hematopoietic cell transplantation are generated at a faster rate in the first 3 months compared with later posttransplantation. Biol Blood Marrow Transplant 2010;16:1658-1664.
9. Korbling M, Katz RL, Khanna A et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002;346:738-746. (Pubitemid 34983994)
10. Badiavas EV, Abedi M, Butmarc J et al. Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol 2003;196:245-250. (Pubitemid 36775870)
11. Hematti P, Sloand EM, Carvallo CA et al. Absence of donor-derived keratinocyte stem cells in skin tissues cultured from patients after mobilized peripheral blood hematopoietic stem cell transplantation. Exp Hematol 2002;30:943-949. (Pubitemid 34838896)
12. Fan Q, Yee CL, Ohyama M et al. Bone marrow-derived keratinocytes are not detected in normal skin and only rarely detected in wounded skin in two different murine models. Exp Hematol 2006;34:672-679.
13. Ishii G, Sangai T, Sugiyama K et al. In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells 2005;23:699-706.
14. Fathke C, Wilson L, Hutter J et al. Contribution of bone marrow-derived cells to skin: Collagen deposition and wound repair. Stem Cells 2004;22:812-822. (Pubitemid 39166938)
15. Chino T, Tamai K, Yamazaki T et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 2008;173:803-814.
16. Fujita Y, Abe R, Inokuma D et al. Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice. Proc Natl Acad Sci USA 2010;107:14345-14350.
17. Tolar J, Ishida-Yamamoto A, Riddle M et al. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 2009;113:1167-1174.
18. Wagner JE, Ishida-Yamamoto A, McGrath JA et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010;363:629-639.
19. Fine JD, Eady RA, Bauer EA et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008;58:931-950.
20. Konig A, Lauharanta J, Bruckner-Tuderman L. Keratinocytes and fibroblasts from a patient with mutilating dystrophic epidermolysis bullosa synthesize drastically reduced amounts of collagen VII: Lack of effect of transforming growth factor-beta. J Invest Dermatol 1992;99:808-812. (Pubitemid 23002046)
21. Bruckner-Tuderman L. Dystrophic epidermolysis bullosa: Pathogenesis and clinical features. Dermatol Clin 2010;28:107-114.
22. Mallipeddi R. Epidermolysis bullosa and cancer. Clin Exp Dermatol 2002;27:616-623. (Pubitemid 35454216)
23. Silver AJ. Treating rare and neglected pediatric diseases: Promoting the development of new treatments and cures. Statement before the U.S. Senate Committee on Health, Education, Labor, and Pensions. Hearing, July 21, 2010. Available at http://help.senate.gov/hearings/hearing/?id=d132692d-5056-9502- 5da9-23c77808a20f.
24. Mecklenbeck S, Compton SH, Mejia JE et al. A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line. Hum Gene Ther 2002;13:1655-1662. (Pubitemid 35034685)
25. Ortiz-Urda S, Thyagarajan B, Keene DR et al. Stable nonviral genetic correction of inherited human skin disease. Nat Med 2002;8:1166-1170. (Pubitemid 35175973)
26. Woodley DT, Keene DR, Atha T et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 2004;10:693-695. (Pubitemid 38937633)
27. Murauer EM, Gache Y, Gratz IK et al. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. J Invest Dermatol 2011;131:74-83.
28. Wong T, Gammon L, Liu L et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008;128:2179-2189.
29. Conget P, Rodriguez F, Kramer S et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 2010;12:429-431.
30. Yan WF, Murrell DF. Fibroblast-based cell therapy strategy for recessive dystrophic epidermolysis bullosa. Dermatol Clin. 2010;28: 367-370, xii.
31. Heinonen S, Mannikko M, Klement JF et al. Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: A model for recessive dystrophic epidermolysis bullosa. J Cell Sci 1999;112(Pt 21):3641-3648.
32. Kiel MJ, Yilmaz OH, Iwashita T et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005;121:1109-1121. (Pubitemid 40884400)
33. Mellerio JE, Weiner M, Denyer JE et al. Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol 2007;46:795-800. (Pubitemid 47162777)
34. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009;17:939-946.
35. Alexeev V, Uitto J, Igoucheva O. Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder. Cytotherapy. 2011;13:30-45.
36. Ko MS, Marinkovich MP. Role of dermal-epidermal basement membrane zone in skin, cancer, and developmental disorders. Dermatol Clin 2010;28:1-16.
37. Kern JS, Loeckermann S, Fritsch A et al. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: High stability of collagen VII favors long-term skin integrity. Mol Ther 2009;17:1605-1615.
38. Fritsch A, Loeckermann S, Kern JS et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 2008;118:1669-1679. (Pubitemid 351632371)
39. Kiuru M, Itoh M, Cairo MS et al. Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin 2010;28:371-382, xii-xiii.
40. Petrova A, Ilic D, McGrath JA. Stem cell therapies for recessive dystrophic epidermolysis bullosa. Br J Dermatol 2010;163:1149-1156.
41. Inokuma D, Abe R, Fujita Y et al. CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes. Stem Cells 2006;24:2810-2816. (Pubitemid 46053018)
42. Sasaki M, Abe R, Fujita Y et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by trans-differentiation into multiple skin cell type. J Immunol 2008;180: 2581-2587.
43. Aristotle. In: Wicksteed PH, Cornford, FM, trans. Aristotle: The Physics Books I-IV (Loeb Classical Library, Bks 1-4). Vol. 228. Cambridge, MA: Harvard University Press, 1957.
44. Deng W, Han Q, Liao L et al. Engrafted bone marrow-derived flk-(1+) mesenchymal stem cells regenerate skin tissue. Tissue Eng 2005;11:110-119.
45. Mansilla E, Marin GH, Sturla F et al. Human mesenchymal stem cells are tolerized by mice and improve skin and spinal cord injuries. Transplant Proc 2005;37:292-294. (Pubitemid 40459765)
46. Tolar J, Xia L, Riddle MJ et al. Induced Pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2011;131:848-56.
47. Chen M, Kasahara N, Keene DR et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 2002;32:670-675. (Pubitemid 35435183)
48. Woodley DT, Remington J, Huang Y et al. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 2007;15:628-635.
49. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol 2010;11:457-460.
50. Almaani N, Nagy N, Liu L et al. Revertant mosaicism in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2010;130:1937-1940.
51. Pasmooij AM, Garcia M, Escamez MJ et al. Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2010;130:2407-2411.
52. Lai-Cheong JE, McGrath JA, Uitto J. Revertant mosaicism in skin: Natural gene therapy. Trends Mol Med 2011;17:140-148.
53. Gregory JJ, Jr., Wagner JE, Verlander PC et al. Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA 2001;98:2532-2537. (Pubitemid 32209516)
54. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142.